
IOVA Shareholders Have The Right To Lead The Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact The DJS Law Group To Discuss Your Rights - ELV
LOS ANGELES, June 9, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA ) for violations of the federal securities laws.
Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.
CASE DETAILS: The complaint alleges that the Company made false and misleading statements to the market concerning whether Iovance's new Authorized Treatment Centers ("ATCs") suffered from longer timelines to begin treatment with Amtagvi than expected. The Company's sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company's failure to match ATCs with manufactured product led to lower revenues and higher costs.
If you are a shareholder who suffered a loss, contact us to participate .
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- NDAE Exchange Unveils NDAE Academy 2.0 For Crypto Learning Advancement
- Tommaso Caratelli Introduces Zerix, Focusing On Innovative Risk Strategies
- David Kinitsky Joins Everstake As CEO To Drive Institutional Growth, Investment And Global Expansion
- Variational Announces $1.5 Million Strategic Round And Launches Referral Program
- Mezo Launches First Full-Stack Bitcoin Economy To Mainnet
- Bitcoin For AI 2025 To Gather Industry Leaders For Virtual Conference
Comments
No comment